Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

Next Previous
Trial Profile

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications Rhinitis
  • Focus Therapeutic Use
  • Sponsors Johnson & Johnson Consumer Companies

Most Recent Events

  • 01 Mar 2021 As per the results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology,interim analysis showed the study could be terminated for efficacy with N 206, since the primary efficacy endpoint demonstrated significant results.
  • 01 Mar 2021 Status changed to discontinued as per the results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 01 Mar 2021 Primary endpoint (Mean Change from Baseline in 24-hour Reflective Total Nasal Symptom Score (rTNSS)) has been met as per the results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top